Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2017 pubmed 29 citations

Humanin analogue, S14G-humanin, has neuroprotective effects against oxygen glucose deprivation/reoxygenation by reactivating Jak2/Stat3 signaling through the PI3K/AKT pathway.

Gao. Guang-Sheng GS; Li. Yun Y; Zhai. Heng H; Bi. Jing-Wen JW; Zhang. Fu-Sen FS; Zhang. Xiao-Ying XY; Fan. Shao-Hua SH

Key Findings

  • HNG is about 1,000 times more active than regular humanin in lab tests
  • HNG at 1 µg/L prevented cell death and oxidative stress in a stroke‑like model
  • The protective effect depends on the Jak2/Stat3 pathway, which is activated through PI3K/AKT signaling

Practical Outcomes

  • While the results are promising, they are limited to cell culture and don’t tell us how to safely use HNG in humans. Biohackers should view this as early‑stage evidence that a stronger humanin analogue might one day help protect the brain, but more animal and clinical research is needed before any dosage or supplement protocol can be recommended.

Summary

A lab study found that a modified version of the tiny protein humanin, called S14G‑humanin (HNG), can protect brain‑like cells from damage that mimics a stroke, mainly by turning on a cell‑survival pathway (Jak2/Stat3 via PI3K/AKT). The effect was strongest at a very low concentration (1 µg/L) in a dish, but the work was done only in cells, not people.

Abstract

Stroke, characterized by a disruption of blood supply to the brain, is a major cause of morbidity and mortality worldwide. Although humanin, a 24-amino acid polypeptide, has been identified to have multiple neuroprotective functions, the level of humanin in plasma has been demonstrated to decrease with age, which likely limits the effects against stroke injury. A potent humanin analogue, S14G-humanin (HNG), generated by replacement of Ser14 with glycine, has been demonstrated to have 1,000-fold stronger biological activity than humanin. The present study established an <i>in vitro</i> oxygen glucose deprivation/reoxygenation (OGD/R) model using SH-SY5Y neuroblastoma cells to mimic the <i>in vivo</i> ischemia/reperfusion injury in stroke. Adding HNG (0-10 &#xb5;g/l) to SH-SY5Y cells to different extents blocked OGD/R-induced reduction of cell viability and antioxidative capacity, as well as decreased the elevated apoptosis rate induced by OGD/R, with the most evident effects at 1 &#xb5;g/l HNG. Janus kinase 2 (Jak2)/signal transducer and activator of transcription 3 (Stat3) signaling was attenuated in OGD/R processes, yet reactivated with HNG treatment. FLLL32 (5 &#xb5;M), a specific inhibitor of the signal, abolished effects of HNG on anti-apoptosis and antioxidation in OGD/R processes. Co-treatment with HNG and FLLL32 failed to interrupt upregulation of cytochrome <i>c</i>, B-cell lymphoma 2-associated X protein and cleaved caspase-3 provoked by OGD/R. Similar to FLLL32, Jak2/Stat3 signaling activated by HNG was also repressed by inhibitor of phosphoinositide 3-kinase (PI3K; 10 &#xb5;M LY294002) or protein kinase B (AKT; 5 &#xb5;M MK-2206 2HCl). These data collectively indicated that HNG has neuroprotective effects against OGD/R by reactivating Jak2/Stat3 signaling through the PI3K/AKT pathway, suggesting that HNG may be a promising agent in the management of stroke.

Study Information

Provider

pubmed

Year

2017

Date

2017-08-16T00:00:00.000Z

DOI

10.3892/etm.2017.4934

Citations

29

References

35